189 completed. 189 Phase 2, 23 Phase 1, 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 189 | Completed 189 |
| Phase 1 | 23 | Completed 23 |
| Phase 3 | 15 | Completed 15 |
Follow Dyskinesias: new trials by email Literature Review of Dyskinesias trials Research Report on Dyskinesias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders Zinc Acetate Dihydrate - GNAO1, Dystonia | Phase 2 | Completed | Children's University Hospital Cologne, Germany | 13 | 2024-08-02 | 2026-02-03 |
| Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia Rapamune (sirolimus/rapamycin) - Ataxia-Telangiectasia (A-T), Ataxia-Telangiectasia | Phase 2 | Completed | Sara Elva Espinosa Padilla, MD | 6 | 2024-07-11 | 2026-09-15 |
| Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients MBF-015 16 mg oral capsules - Huntington Disease | Phase 2 | Completed | Medibiofarma S.L. | 10 | 2024-02-01 | 2025-03-03 |
| Life's End Benefits of cannaBidiol and tetrahYdrocannabinol T2:C100, Placebo - Agitation, Dementia | Phase 2 | Completed | University of Southern California | 120 | 2024-01-05 | 2026-09-02 |
| A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease Placebo, Suvecaltamide - Parkinson Disease, Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 169 | 2022-12-01 | 2026-01-15 |
| Efficacy and Safety on SOM3355 in Huntington's Disease Chorea Placebo capsules, SOM3355 200 mg capsules, SOM3355 300 mg capsules - Huntington Chorea | Phase 2 | Completed | SOM Innovation Biotech SA | 139 | 2022-08-02 | 2025-08-28 |
| A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) PTC518, Placebo - Huntington Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 159 | 2022-06-03 | 2026-06-16 |
| 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease SAGE-718, Placebo - Huntington Disease | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 69 | 2022-05-26 | 2025-09-15 |
| Intramuscular Ketamine Effect on Postnasal Surgery Agitation Ketamine Hydrochloride - Agitation, Emergence | Phase 2 | Completed | Jordanian Royal Medical Services | 193 | 2022-05-11 | 2023-01-25 |
| Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis Triheptanoin - Ataxia Telangiectasia | Phase 2 | Completed | The University of Queensland | 30 | 2022-03-15 | 2023-07-20 |
| A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) SAGE-718, Placebo - Huntington's Disease | Phase 2 | Completed | Supernus Pharmaceuticals, Inc. | 189 | 2022-01-26 | 2025-09-15 |
| A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) JZP385, Placebo - Essential Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 420 | 2021-12-06 | 2025-07-24 |
| Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia NLX-112, Placebo - Medication-Induced Dyskinesia | Phase 2 | Completed | Neurolixis SAS | 27 | 2021-11-09 | 2024-04-23 |
| Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia CPL500036 - low dose, CPL500036 - high dose, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Completed | Celon Pharma SA | 105 | 2021-11-02 | 2025-03-04 |
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Dipraglurant, Placebo - Blepharospasm, Dystonia | Phase 2 | Completed | Addex Pharma S.A. | 15 | 2021-10-06 | 2025-10-03 |
| Study of WVE-003 in Patients With Huntington's Disease SAD: 30mg WVE-003, SAD: 60mg WVE-003, SAD: 90mg WVE-003 - Huntington Disease | Phase 1 / Phase 2 | Completed | Wave Life Sciences USA, Inc. | 47 | 2021-09-06 | 2025-08-12 |
| Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia ABP-450 - Cervical Dystonia | Phase 2 | Completed | AEON Biopharma, Inc. | 51 | 2021-07-27 | 2024-08-22 |
| Chinese Medicine WT for Spinocerebellar Ataxia Type 3 Chinese medicine WT - Ataxia, Spinocerebellar, Insulin-Like Growth Factor I | Phase 2 | Completed | Changhua Christian Hospital | 33 | 2021-05-31 | 2023-01-31 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia ABP-450, Placebo - Cervical Dystonia | Phase 2 | Completed | AEON Biopharma, Inc. | 61 | 2021-03-29 | 2024-02-14 |
Showing 20 of 189. Sign in to see all of them.
Huntington Disease (46) · Parkinson Disease (38) · Psychomotor Agitation (24) · Dystonia (14) · Tremor (14) · Movement Disorders (13) · Alzheimer Disease (10) · Ataxia (10) · Tardive Dyskinesia (10) · Torticollis (10) · Spinocerebellar Ataxias (8) · Chorea (7) · Dementia (7) · Essential Tremor (7)
Nervous System Diseases (179) · Central Nervous System Diseases (155) · Neurologic Manifestations (148) · Pathological Conditions, Signs and Symptoms (143) · Signs and Symptoms (140) · Brain Diseases (128) · Neurodegenerative Diseases (116) · Movement Disorders (103) · Basal Ganglia Diseases (88) · Mental Disorders (81) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (75) · Genetic Diseases, Inborn (75) · Heredodegenerative Disorders, Nervous System (70) · Neurocognitive Disorders (63)
mavoglurant (8) · Levodopa (7) · Creatine (5) · Dexmedetomidine (5) · Botulinum Toxins, Type A (4) · Saline Solution (4) · Sodium Chloride (4) · valbenazine (4) · Cannabidiol (3) · Dronabinol (3) · Lithium Carbonate (3) · pridopidine (3) · talampanel (3) · triheptanoin (3) · 2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline (2)
National Institute of Neurological Disorders and Stroke (NINDS) (24) · Novartis Pharmaceuticals (6) · Massachusetts General Hospital (4) · Neurocrine Biosciences (4) · Novartis (4) · BioXcel Therapeutics Inc (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · University of South Florida (3) · Yale University (3) · AEON Biopharma, Inc. (2) · Addex Pharma S.A. (2) · Avanir Pharmaceuticals (2) · Charite University, Berlin, Germany (2) · Federico II University (2) · Icahn School of Medicine at Mount Sinai (2)
United States (123) · Germany (29) · Canada (27) · France (22) · Italy (18) · Spain (17) · United Kingdom (15) · Australia (11) · Poland (9) · Netherlands (6) · Austria (5) · Hungary (5) · Japan (5) · Slovakia (5) · Switzerland (4)
Diana Rosas, MD, MS (3) · Alan Percy, MD (2) · BioXcel MM, MD (2) · Carlos Gordon, Prof. (2) · Chris O'Brien, MD (2) · Josef Priller, MD (2) · Joseph Jankovic (2) · Karl Kieburtz, MD, MPH (2) · Leigh J Beglinger, Ph.D. (2) · Michael H. Bloch, MD, MS (2) · Steven M Hersch, MD, PhD (2) · Theresa Zesiewicz, MD (2) · Timothy Feyma, MD (2)
PMID 36463457, PMID 21484867, PMID 27214258, PMID 31356217, PMID 31381524, PMID 31617235, PMID 34532852, PMID 36811812, PMID 37460385, PMID 38363467, PMID 11130527, PMID 14718713, PMID 15210907, PMID 16763896, PMID 16934683, PMID 17826341, PMID 18334537, PMID 19454032, PMID 19838774, PMID 19841031, PMID 20090835, PMID 20142523, PMID 20201005, PMID 20483969, PMID 20599042, PMID 20606544, PMID 21211990, PMID 21294997, PMID 21555779, PMID 21594724, PMID 21765198, PMID 22144182, PMID 22454323, PMID 22875082, PMID 22927201, PMID 23013802, PMID 23257314, PMID 23408867, PMID 23611363, PMID 23853029, PMID 24001701, PMID 24144615, PMID 24236946, PMID 24375941, PMID 24399647, PMID 24806873, PMID 25062857, PMID 25063332, PMID 25467848, PMID 25568297
2014 (3), 2008 (2), 2009 (1), 2015 (1), 2016 (1), 2017 (1), 2018 (1), K23NS055733 (1), P01NS058793 (1), R01AG047146 (1), R01AG050515 (1), R01AG068324 (1), R01AG095004 (1), R01DC012545 (1), R01MH070802 (1)